Good Year for Eli Lilly Driven By Prozac

20 February 1995

Strong growth in sales of the antidepressant Prozac (fluoxetine), up 39% to $1.7 billion, drove Eli Lilly's good performance in 1994. For the year, sales were ahead 10% to $5.7 billion, with worldwide volume growth of 11%. Net income was $1.3 billion and earnings per share were $4.45 after charges associated with a voluntary product recall of three liquid antibiotics and the impact of the acquisitions of Sphinx Pharmaceuticals and PCS Health Systems. Excluding these charges, net income would have been $1.4 billion and EPS $4.84.

Worldwide sales of pharmaceuticals in 1994 advanced 10% to $5.2 billion. In addition to sales growth by Prozac, other products contributing to volume growth were the antiulcerant Axid (nizatidine), a human growth hormone Humatrope, and an insulin product Humulin. Sales of anti-infectives declined as international growth was offset by a decline in the USA due primarily to continued competitive pressures.

Sales growth in the USA amounted to 6% and international turnover increased 17%. R&D spending for the year was $240.4 million, up 11%.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight